In this YouTube short, interviewer Speaker A asks McCall McPherson how a patient on Synthroid might discontinue the medication. McPherson responds that stopping Synthroid must be evaluated individually, requiring review of the patient’s pre‑treatment lab results and whether they have Hashimoto’s thyroiditis. She notes a subset of patients without Hashimoto’s who exhibit what she calls a "pure conversion disorder," meaning they produce adequate thyroid hormone but struggle to activate it effectively, which influences the decision to taper or stop Synthroid.
Questions this video answers
It’s evaluated on a case‑by‑case basis. One must review the patient’s labs before starting Synthroid and determine if they have Hashimoto’s. For patients without Hashimoto’s who may have a pure conversion disorder—producing enough hormone but struggling to activate it—the approach to tapering or stopping Synthroid will differ.
